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gained. Sensitivity analyses show that vaccine efﬁ cacy and whether vaccine is life-long
protective are the most inﬂ uential parameters impacting model outcomes. ICER
changed to 71.11% if the efﬁ cacy is down to 70%, 32.60% if the efﬁ cacy is 100%; 
and 200.04% if the vaccine provides only 10 year protection. CONCLUSIONS: These
results show that HPV vaccine is cost-effective compared to screening alone. Further 
studies should be done to establish more precise model parameters, such as vaccine
efﬁ cacy, duration, adverse event rates and cost for adverse events.
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OBJECTIVES: To determine whether the use of i.v. Daptomycin or i.v. Vancomycin
is the most cost-effective alternative for the treatment of infective endocarditis in public
health care institutions in Mexico METHODS: A cost-effectiveness study was per-
formed considering an institutional perspective and comparing the use of the evaluated 
alternatives as ﬁ rst-line antibiotic therapy. A systematic review was performed in order
to collect data about clinical success, length of stay at hospital services and adverse
events due to the use of either i.v. Daptomycin or i.v. Vancomycin. The use of resources 
matrix considered the selected antibiotic therapy, concomitant medication, length of 
stay at hospital services, and a second-line antibiotic therapy in case of failure. A 
decision tree with Bayesian approach was designed to simulate the use of resources.
Patient’s outcomes were supposed to be clinical success (in either short hospital stay 
or long hospital stay) and therapeutic failure which can be caused by death or lack
of efﬁ cacy of the antibiotic. Results were evaluated with incremental analysis and 
one-way sensitivity analysis of the most uncertain variables were also conducted. 
RESULTS: The use of i.v. Daptomycin results in the lowest total cost (DAP: $7,847.00 
USD; VAN:$7,990.00 USD) and the lowest cost per clinical success (CS) (DAP:
$17,754.00 USD/CS; VAN:$23,083.00 USD/CS) compared with i.v. Vancomycin. The 
sensitivity analysis varying clinical success rates of every evaluated alternative showed 
robustness of base study. CONCLUSIONS: Daptomycin is the most cost-effective
alternative in the treatment of Infective Endocarditis and MRSA Bacteremia when 
used as ﬁ rst-line antibiotic therapy, since its use reduces the length of hospital stay 
reducing expenses of public health system budget in Mexico. The use of Daptomycin
can be considered as safer when compared to use Vancomycin, because it has been 
reported less frequently event adverse in long term treatments.
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OBJECTIVES: Polymyxin B-immobilized hemoperfusion cartage (PMX) is a medical
device for the treatment of severe sepsis by adsorbing and eliminating plasma endo-
toxin. The objective of this study is to assess the clinical effectiveness and cost-
effectiveness of PMX vs. conventional therapy in treating patients with severe sepsis. 
METHODS: For a systematic review, we searched OVID, EMBASE and Cochrane 
central register of controlled trial (CENTRAL). Inclusion criteria of clinical trials were
RCTs on ‘sepsis’, ‘severe sepsis’ and ‘septic shock’ patients. We included those studies
that reported at least one of the four speciﬁ ed outcomes: mortality, plasma endotoxin
level, days of ICU stay and blood pressure. Relevant outcomes were synthesized using 
RevMan 5.0. The average medical cost of sepsis was estimated from a national health 
insurance (NHI) claims database and the PMX related cost was calculated from the 
fee schedule of NHI. For economic evaluation, we assessed incremental cost effective-
ness ratio (ICER) of PMX compared with conventional therapy. The assessment was
performed from a purchaser’s perspective. RESULTS: A total of 11 RCTs were identi-
ﬁ ed with pooled sample size of 802; 477 in PMX and 325 in conventional therapy 
group. Meta-analysis results showed that PMX therapy had signiﬁ cantly lower mortal-
ity risk. The 28-day mortality rate of PMX group and conventional therapy group
were 35.4% and 70.4% respectively with risk ratio of 0.51 (95% CI, 0.43–0.59). The
medical cost for sepsis turned out 3,536,000 KRW per patient, which is common in 
PMX and conventional treatment. The additional cost related to PMX treatment was 
estimated to be KRW5,496,984 KRW per patient. Applying this mortality outcome
and cost data, we produced an ICER of KRW15,705,669 per life gained. CONCLU-
SIONS: Compared with conventional therapy alone, PMX therapy with conventional
therapy for the treatment of severe sepsis was found clinically superior and cost-
effective as well.
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OBJECTIVES: Streptococcus pneumoniae infections in adults are associated with
substantial morbidity, mortality, and costs. The objective of this study was to provide 
an analysis of the conclusions and assumptions of published studies on the cost-
effectiveness of pneumococcal polysaccharide vaccination (PPV-23 (23 serotypes)) in
adults. METHODS: A search of recent literature (1997–2008) was conducted to 
identify cost-effectiveness studies pertaining to the use of PPV for the prevention of 
invasive pneumococcal disease (IPD) in adults. A structured review of the impact of 
model assumptions on cost-effectiveness ratios was undertaken. Cost per life year
gained (LYG) or quality adjusted life year (QALY) were reported in 2007 US dollars. 
RESULTS: The literature search identiﬁ ed 31 studies, 19 of which reported some cost
data but did not include cost–effectiveness data for PPV-23 vaccination. All but one 
of the remaining twelve studies compared PPV-23 vaccination with no vaccination, 
and these were included in this analysis. Vaccination of over 65 year olds with PPV-23 
for the prevention of IPD was found to be cost-effective with incremental cost effective-
ness ratios ranging from 2007 $9,810 to $26,160 per LYG and from $9.08 (cost-
saving) to $53,955 per QALY. Review of model parameters revealed that the results 
of these studies have to be considered in the light of limitations of available data on 
vaccine effectiveness, disease incidence, and case-fatality ratios. CONCLUSIONS: All 
the reviewed studies reported that PPV-23 is a cost-effective, and in some cases a
cost-saving, vaccination strategy for the prevention of IPD in the elderly. Further eco-
nomic evaluation of PPV-23 may be warranted based on the availability of new data 
on vaccine efﬁ cacy, IPD incidence and case fatality in the adult population in the
post-PCV-7 era.
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OBJECTIVES: To investigate how the cost-effectiveness of preventing or treating 
HIV/AIDS varies by a series of potentially relevant external factors. METHODS:
We reviewed the cost-effectiveness evidence for HIV/AIDS prevention and treat-
ment in the Cost-Effectiveness (CEA) Analysis Registry at Tufts Medical Center
(www.cearegistry.org) from 2002–06, and then constructed efﬁ cient frontier curves 
(EF curve) in terms of incremental cost per QALY ratios based on extracted evidence 
using methods introduced by Institute for Quality and Efﬁ ciency in Health Care
(IQWiG), Germany. All articles that report cost-effectiveness as USD/QALYs were
selected, including information on the following factors: payer perspective; prevention 
stage; intervention type, and country of study. We excluded articles with time horizon
30 years and those without discounting. RESULTS: Of 237 eligible articles in the 
CEA Registry, we extracted 11 HIV/AIDS-related articles, which included 84 individ-
ual cost-effectiveness (CE) ratios. Plotted EF curves were visually distinct, depending
on the prevention type, with primary prevention interventions being most efﬁ cient.
With respect to country, the EF curve for the U.S. and South Africa were separate,
with the curve for South Africa lying near the vertical axis, reﬂ ecting low cost per
QALY ratios for interventions studied. Subgrouping by payer perspective (societal or 
health care payer) and intervention type (pharmaceutical, education, and screening)
did not affect the separation of the lines. CONCLUSIONS: The CE ratio clustering 
in HIV/AIDS was found on the C-E plane, which suggested separate EF curves should
be considered by stratifying by prevention stage and country. These results may differ
for other diseases, but this analysis shows that stratiﬁ ed EF analysis could help to
develop a deeper appreciation of cost-effectiveness beyond crude cost per QALY ratios
without stratiﬁ cation.
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OBJECTIVES: Vaccination of elderly and at-risk population against Streptococcus 
pneumonia is recommended and partially reimbursed in Turkey due to the substantial 
medical and economic burden. However, only ^2% of these populations were vacci-
nated in 2007. A three-step economic analysis was designed to measure the burden 
of pneumococcal infections (pneumonia and bacteremia) from a public payer perspec-
tive in elderly (60 years) and at-risk adults (18–59 years), and to evaluate the beneﬁ ts 
of implementing a vaccination program. METHODS: Firstly, we evaluated the cost 
of pneumonia and bacteremia in retrospective and prospective studies in public 
hospital services in Ankara. Secondly, a static model was used to evaluate cost-
effectiveness of vaccination in the two targeted populations using demographic and
epidemiological data obtained from Turkish sources or, when unavailable, from inter-
national literature. A stochastic Monte Carlo simulation estimated the incremental 
cost-effectiveness ratio in Euros (€) per life year gained (LYG), assuming that vaccina-
tion protected for 5 years with 50–70% effectiveness against pneumococcal bacteremia 
